John Paul II Medical Research Institute - Personalized Medicine...

top of page

Back to FAQ Regarding COVID-19 Vaccines

Back to Coronavirus Research

Back to Coronavirus Research

Back to iPS Cell Biobank

Research

Research Overview

Institute Goals

Non-Profit Biotech Model

Gene Therapy vs. Cell Therapy

Specific Research Programs

iPS Cell Biobank

Secular Biotechnologies That Threaten Catholic Healthcare

Personalized Medicine in Oncology

C oronavirus Research

Research Milestones

Personalized Medicine in Oncology

Where Are We Now and Where is the Future?

Drug Susceptibility and Drug Resistance in Cancer is More Complicated Than Bacterial Resistance

Actionable Cancer Protein or Gene Mutation Biomarkers Are Present in Only A Minority of Cancers

A Bottom Line Review of Cancer Genomic Testing

Cancer and Mouse Models - The Pros and Cons

Drug Testing in Live Cultured Cancer Cells is Making A Comeback

Cancer Stem Cells - A Cause for Metastasis, Drug Resistance and Recurrence

iPS Cell Reprogramming Technology - A Method For Producing Patient-Specific Cancer Stem Cells

The Institute is Poised to Create Cancer Stem Cells From Patients, Create 3-D Tumor Models and Perform Drug Testing on 3-D Models

What Are the Scientific and Clinical Gaps in Cancer Personalized Medicine?

bottom of page